Approximately one-third of patients with relapsed or refractory mantle cell lymphoma (MCL) in this study treated with CAR T-cell therapy experienced disease progression, with a median progression time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback